Indications -- Psoriasis/Chronic Inflammation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- Psoriasis/Chronic Inflammation

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Icebrg who wrote (288)	10/18/2002 9:15:19 AM
From: nigel bates	Read Replies (1) of 631

LFA-1 Novartis ZURICH, Oct 18 (Reuters) - Novartis AG (NOVZn.VX) has agreed to license experimental LFA-1 antagonist drugs from Japan's Tanabe Seiyaku Co Ltd (Tokyo:4508.T - News) for potential use in treating inflammatory autoimmune diseases, the Swiss healthcare group said on Friday. It gave no financial terms in a statement. The deal gives Novartis exclusive rights to develop and market LFA-1 antagonists in the United States, Europe and many other countries excluding Japan and some other Asian countries....

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next